Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Re:NewCell on its IPO
Mandate

Vinge advises Re:NewCell on its IPO

November 27, 2020 Banking and Finance M&A Corporate Tax Capital Markets and Public M&A

Vinge advises Re:NewCell AB in connection with its listing on Nasdaq First North Premier Growth Market.

The company is the first in the world to commercially offer a dissolving pulp for textile production manufactured from 100 per cent recycled textiles.

The Vinge team includes Christian Lindhé, Erik Sjöman, Ludvig Frithiof and Nora Gullberg (Capital Markets and Public M&A), Henrik Ossborn and Jack Bengtsson (Banking and Finance), Anna Edström and Martin Svanberg (M&A) as well as Maria Schultzberg (Tax).

Related

Vinge advises Aspo on its acquisition of Swed Handling

 Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

 Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024